ACP-196

Known as: Bruton Tyrosine Kinase Inhibitor ACP-196 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2017
2017
BACKGROUND Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Review
2016
Review
2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class… (More)
  • table 1
  • table 2
Is this relevant?
2015
2015
Background: Signaling through the B-cell receptor (BCR) results in cell survival and proliferation, and this pathway is critical… (More)
Is this relevant?
2015
2015
Ibrutinib, a first generation Btk inhibitor, is approved for the treatment of CLL and mantle cell lymphoma; known toxicities… (More)
Is this relevant?
2015
2015
Introduction: BTK is involved in B-cell receptor (BCR) signal transduction and is an established target for the treatment of… (More)
Is this relevant?
2015
2015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Pancreatic ductal adenocarcinoma exists in a… (More)
Is this relevant?
2015
2015
Acalabrutinib (ACP-196), a second-generation BTK inhibitor, has demonstrated high response rates in patients with chronic… (More)
Is this relevant?
2014
2014
Recent recognition of B-cell receptor (BCR) signaling as a critical factor in the progression of B-cell malignancies, including… (More)
Is this relevant?